IQVIA (NYSE:IQV) Price Target Lowered to $261.00 at Truist Financial

IQVIA (NYSE:IQV) had its price objective trimmed by Truist Financial from $265.00 to $261.00 in a report issued on Thursday morning,Benzinga reports. The firm currently has a buy rating on the medical research company’s stock.

A number of other research analysts have also recently weighed in on the stock. StockNews.com cut shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Thursday, November 28th. Evercore ISI dropped their price objective on IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. Redburn Atlantic assumed coverage on IQVIA in a research note on Monday, October 14th. They set a “buy” rating and a $276.00 target price on the stock. Leerink Partners restated an “outperform” rating and issued a $248.00 price target (down from $260.00) on shares of IQVIA in a research note on Tuesday, November 19th. Finally, Morgan Stanley reduced their price objective on shares of IQVIA from $280.00 to $265.00 and set an “overweight” rating on the stock in a research report on Monday, November 4th. Four analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $257.60.

IQVIA Trading Down 0.3 %

IQVIA stock opened at $200.37 on Thursday. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. IQVIA has a 12-month low of $187.62 and a 12-month high of $261.73. The firm has a market capitalization of $36.37 billion, a price-to-earnings ratio of 26.30, a P/E/G ratio of 2.07 and a beta of 1.49. The firm has a 50 day moving average of $212.86 and a 200 day moving average of $224.44.

Hedge Funds Weigh In On IQVIA

Several large investors have recently modified their holdings of IQV. FMR LLC boosted its stake in IQVIA by 38.7% during the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after buying an additional 804,963 shares during the period. B. Metzler seel. Sohn & Co. Holding AG purchased a new position in shares of IQVIA during the 3rd quarter worth about $147,683,000. 1832 Asset Management L.P. raised its position in IQVIA by 472.3% in the 2nd quarter. 1832 Asset Management L.P. now owns 456,335 shares of the medical research company’s stock worth $96,487,000 after purchasing an additional 376,595 shares during the period. Renaissance Technologies LLC bought a new stake in IQVIA in the second quarter worth about $70,610,000. Finally, Impax Asset Management Group plc boosted its position in shares of IQVIA by 19.3% during the second quarter. Impax Asset Management Group plc now owns 1,635,201 shares of the medical research company’s stock valued at $344,998,000 after buying an additional 264,555 shares during the period. Institutional investors own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.